kabutan

Oncolys BioPharma Inc.(4588) Summary

4588
TSE Growth
Oncolys BioPharma Inc.
1,061
JPY
+150
(+16.47%)
L-Up
Dec 12, 3:30 pm JST
6.81
USD
Dec 12, 1:30 am EST
Result
PTS
outside of trading hours
1,080
Dec 13, 1:10 am JST
Summary Chart Historical News Financial Result
PER
PBR
16.5
Yield
ー%
Margin Trading Ratio
1,106.35
Stock Price
Dec 12, 2025
Opening Dec 12, 9:00 am
918 JPY 5.90 USD
Previous Close Dec 11
911 JPY 5.83 USD
High Dec 12, 1:02 pm
1,061 JPY 6.81 USD
Low Dec 12, 9:22 am
901 JPY 5.78 USD
Volume
6,753,800
Trading Value
6.83B JPY 0.04B USD
VWAP
1011.03 JPY 6.49 USD
Minimum Trading Value
106,100 JPY 681 USD
Market Cap
0.03T JPY 0.18B USD
Number of Trades
15,404
Liquidity & Number of Trades
As of Dec 12, 2025
Liquidity
High
1-Year Average
1,695
1-Year High Oct 9, 2025
18,110
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 700 6,557,100 9367.29
Nov 28, 2025 300 6,398,800 21329.33
Nov 21, 2025 17,200 6,049,200 351.70
Nov 14, 2025 600 5,858,800 9764.67
Nov 7, 2025 4,600 5,525,800 1201.26
Company Profile
Oncolys BioPharma Inc. is a drug discovery venture focusing on rare cancers and severe infectious diseases, utilizing proprietary virus technology.
Sector
Pharmaceuticals
Oncolys BioPharma Inc. promotes the development of cancer virus therapy and severe infectious disease treatments using its proprietary virus genetic modification technology. Its main pipeline includes Telomelysin, which specifically proliferates in cancer cells, and OBP-702, a next-generation Telomelysin with even more potent anti-cancer activity. Additionally, OBP-601, which has been developed as an HIV infection treatment, is now being repurposed as a treatment for neurodegenerative diseases. The company is also developing OBP-2011 as a viral infection treatment. Oncolys BioPharma Inc. is also working on TelomeScan, a cancer diagnostic agent for ultra-early detection or prognosis testing of cancer. The company employs a fabless management strategy to optimize development efficiency and expenses.